Kunming Biomed International Joins Cell Symposia on Molecular Mechanisms and Integrative Physiology of Obesity
Kunming Biomed International (KBI)
KBI is an international CRO specializing in pharmacology studies using non-human primate disease models.
Shanghai, China - October 16, 2023 - Kunming Biomed International (KBI), a leading research institution specializing in non-human primate (NHP) disease models, proudly announces its participation in the prestigious Cell Symposia on Molecular Mechanisms and Integrative Physiology of Obesity. The symposium took place at Shanghai Fudan University from October 13-15, 2023.
As a major contributor in the field of NHP disease models, KBI showcased its commitment to advancing the understanding of obesity by presenting groundbreaking research. KBI's submission, titled "Profiling Obesity in Monkeys into Subtypes for the Translation of Target-Based Precision Medicine," was selected to be presented as a poster during the symposium.
Obesity is a global health challenge, and KBI's pioneering research plays a pivotal role in unraveling the molecular mechanisms and integrative physiology behind this complex condition. By dissecting obesity into subtypes, KBI aims to pave the way for more targeted and precise approaches to treatment and prevention.
Prof. Lichuan Yang, Dr. Jason Ji (also the author), distinguished representatives from KBI, presented the research findings at the symposium, highlighting the institution's dedication to advancing the understanding of obesity and its potential implications for precision medicine.
KBI is committed to fostering collaboration and sharing knowledge with the global scientific community. The participation in the Cell Symposia on Molecular Mechanisms and Integrative Physiology of Obesity is a testament to KBI's commitment to cutting-edge research and its dedication to improving human health.
For more information about KBI and its research initiatives, please visit https://www.kbimed.com
About KBI:
KBI is a leading research institution specializing in NHP disease models. With a mission to advance biomedical research and improve human health, KBI conducts groundbreaking studies across various areas of medical science, including metabolic diseases, ophthalmic diseases and central nervous system diseases.
Senior VP | Global Business Development
1 年Excellent work Lichuan Yang, Jason, and 徐晨Angela Hsu to advance therapeutic treatment options for #obesity and #metabolicdisease.
CTO and Scientific Consultant for Kunming Biomed International (KBI-TriApex Laboratories Co. Ltd.)
1 年Great Job Lichuan and Jason, Congratulation ??